EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

High-Intensity Atorvastatin and 24-Hour Blood Pressure in Obstructive Sleep Apnea: A Randomized, ­Double-Blind, Placebo-Controlled Pilot Study

Joshua M Bock iD, Soumya Vungarala, Sreeja Sompalli, Naima Covassin, Jan Bukartyk, Shahid Karim, Erik St Louis iD, R Scott Wright, Prachi Singh iD, Virend K Somers

American Journal of Hypertension · 2026

DOI: 10.1093/ajh/hpaf202 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift American Journal of Hypertension, 2026. Verfasst von Joshua M Bock und 9 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, United States. Hauptthemen laut MEDLINE: Atorvastatin, Sleep Apnea, Obstructive, Blood Pressure, Hypertension. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NIA NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Obstructive sleep apnea (OSA) is a risk factor for hypertension and some evidence suggests this risk may not be mitigated with positive airway pressure. Low-intensity statin therapy can modestly reduce blood pressure (BP). In this exploratory analysis, we examined if six months of high-intensity statin therapy could lower resting or ambulatory BP in patients with OSA.

Methods

39 patients with OSA (13F, age = 49 ± 9yrs, body mass index = 32.9 ± 4.2kg/m2, apnea-hypopnea index = 22.2 ± 12.4 events/hour) were randomized to high-intensity atorvastatin or placebo. BP was assessed using seated, “office” measurements and in 20-minute intervals over 24 consecutive hours at three timepoints (baseline, three- and six-months post-randomization). Participants maintained a diary denoting sleep and wake times for analysis. Changes (Δ) in BP from baseline were assessed and adjusted for adherence to participants’ intervention (atorvastatin or placebo) as well as to their treatment for OSA (yes or no).

Results

There were no between-group differences in baseline BP variables (P = .09-.96). At three months, the changes in resting (P = .74-.87), 24 hour mean (P = .54-.96), daytime (P = .70-.96), nor nighttime (P = .74-.96) BP did not differ between groups. Similarly, the changes in resting (P = .23-.92), 24 hour mean (P = .51-.82), daytime (P = .17-.78), and nighttime (P = .51-1.00) BP did not differ between groups following six months of their respective intervention.

Conclusions

Our data suggest that high-intensity atorvastatin does not lower resting or ambulatory BP in patients with OSA relative to a placebo. Thus, it does not appear that atorvastatin is a viable adjunct intervention for BP reduction in patients with OSA. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT03308578.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtorvastatinSleep Apnea, ObstructiveBlood PressureHypertensionHydroxymethylglutaryl-CoA Reductase InhibitorsHumansMaleMiddle AgedFemalePilot ProjectsDouble-Blind MethodAdultTreatment OutcomeBlood Pressure Monitoring, AmbulatoryTime Factors

Stichwörter der Autor:innen

blood pressurehypertensionsleep apneastatin

Substanzen

AtorvastatinHydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Departments of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, United States.
  • Neurology and Internal Medicine, Mayo Clinic, Rochester, MN, United States.
  • Sleep and Cardiometabolic Health Laboratory, Pennington Biomedical Research Center, Baton Rouge, LA, United States.

ORCID-Profile: Joshua M Bock, Erik St Louis, Prachi Singh

Förderung

  • NIH HHS
  • NIA NIH HHS
  • NHLBI NIH HHS
  • Mayo Clinic Marie Ingalls Research Career Development
  • NIAMS NIH HHS
  • American Heart Association
  • National Heart, Lung, and Blood Institute
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases

Zitieren

APA

Bock, J. M., Vungarala, S., Sompalli, S., Covassin, N., Bukartyk, J., Karim, S., Louis, E. S., Wright, R. S., Singh, P., & Somers, V. K. (2026). High-Intensity Atorvastatin and 24-Hour Blood Pressure in Obstructive Sleep Apnea: A Randomized, ­Double-Blind, Placebo-Controlled Pilot Study. American Journal of Hypertension. https://doi.org/10.1093/ajh/hpaf202

Vancouver

Bock JM, Vungarala S, Sompalli S, Covassin N, Bukartyk J, Karim S, et al. High-Intensity Atorvastatin and 24-Hour Blood Pressure in Obstructive Sleep Apnea: A Randomized, ­Double-Blind, Placebo-Controlled Pilot Study. American Journal of Hypertension. 2026. doi:10.1093/ajh/hpaf202

BibTeX
@article{Bock2026,
  author = {Bock, Joshua M and Vungarala, Soumya and Sompalli, Sreeja and Covassin, Naima and Bukartyk, Jan and Karim, Shahid and Louis, Erik St and Wright, R Scott and Singh, Prachi and Somers, Virend K},
  title = {High-Intensity Atorvastatin and 24-Hour Blood Pressure in Obstructive Sleep Apnea: A Randomized, ­Double-Blind, Placebo-Controlled Pilot Study},
  journal = {American Journal of Hypertension},
  year = {2026},
  doi = {10.1093/ajh/hpaf202}
}
Kostenlos starten →